INTRODUCTION {#s1}
============

Hepatitis B virus (HBV) infection is a serious public health problem worldwide, with approximately 2 billion people having a history of HBV infection and 350 million of them suffering from chronic HBV infection \[[@R1]\]. Based on a national epidemiological survey, it has been estimated that the weighted prevalence of hepatitis B surface antigen (HBsAg) was roughly 7.18% in Chinese population \[[@R2]\]. Although the host factors (such as infection age, gender and immune status), viral and environmental factors are thought to be involved in affecting the development of CHB. The mechanisms underlying the different clinical outcomes of HBV infection have not been fully understood. Studies indicated that host genetic factors play a critical role in the development of HBV infection, especially single nucleotide polymorphisms (SNPs), is regarded to be one of the determinants for this clinical heterogeneity \[[@R3], [@R4]\]. Some polymorphisms have been reported to be involved in susceptibility to CHB in disease severity and progression, or disease prognosis \[[@R4], [@R5]\].

Telomeres, located at the ends of eukaryotic chromosomes, play a crucial role in maintaining the integrity of chromosome and stability of the genome \[[@R6], [@R7]\]. Telomeres are approximately 10--15 kb in human somatic cells, and they shorten by 50--200 bp after each cycle of mitotic division \[[@R8]\]. In general, the incomplete replication of linear DNA molecules and gradual shortening of telomere length lead to regulated cell senescence and apoptosis or cell death. It has been reported that telomere length is associated with chronic liver diseases \[[@R9]\], CHB and hepatocellular carcinoma \[[@R10]\]. Interestingly, previous studies demonstrated that a number of polymorphisms in telomere biology gene (telomerase reverse transcriptase, *TERT*) are significantly associated with telomere length \[[@R11]--[@R13]\]. In addition, a recent report indicated the genotype TT of *TERT* polymorphism rs2736098 is associated with a decreased risk of CHB in Chinese males \[[@R14]\].

The *TERT* gene, located at human chromosome band 5p15.33, consists of 16 exons and 15 introns spanning about 35 kb. As the reverse transcriptase catalytic subunit of telomerase, the TERT is essential for the maintenance of telomere DNA length in chromosomes \[[@R15]\]. The activation of telomerase plays a key role in cellular immortalization and the malignant transformation of human cells. This activation requires the TERT catalyst \[[@R16]\]. A number of studies have also reported that variants of *TERT* gene are associated with a significantly higher susceptibility to several cancers \[[@R17]--[@R20]\]. However, to date, little study is reported on the association between genetic variations in the *TERT* gene and the risk of CHB. In this study, we conducted a case-control study consisting of 242 CHB patients and 300 healthy controls to investigate the association between the four common genetic variants in *TERT* and the risk CHB in a Chinese Han population.

RESULTS {#s2}
=======

Participants {#s2_1}
------------

The basic characteristic of the participants are shown in Table [1](#T1){ref-type="table"}, including gender, age, smoking and drinking. A total of 242 CHB patients (188 males and 54 females) with a mean age of 50.04 (± 12.048) years and 300 healthy controls (180 males and 120 females) with a mean age of 60.42 (± 5.143) years were enrolled in the study. There were significant differences in gender, smoking, drinking and age distribution between the CHB cases and control groups (*P* \< 0.05) (Table [1](#T1){ref-type="table"}). In order to eliminate those residual confounding effects, the variable of gender, smoking, drinking and age were adjusted in later multivariate unconditional logistic regression analysis.

###### Basic characteristic of the participants

  Characteristic   Case (*N* = 242)    Frequency        Control (*N* = 300)   Frequency       *P*-value   
  ---------------- ------------------- ---------------- --------------------- --------------- ----------- ----------
  Gender           female              54               22.3%                 120             40.0%       \< 0.001
  male             188                 77.7%            180                   60.0%                       
  Smoking          Yes                 126              52.1%                 89              29.7%       \< 0.001
  No               116                 47.9%            189                   63.0%                       
  Drinking         Yes                 90               37.2%                 79              26.3%       0.033
  No               152                 62.8%            199                   66.3%                       
  Age              years (mean ± SD)   50.04 ± 12.048                         60.42 ± 5.143               \< 0.001

SD: Standard deviation *P* \< 0.05 indicates statistical significant. The smoking and drinking information of the 22 cases in the control group were missing.

Allele distributions {#s2_2}
--------------------

The detailed data of each SNP in *TERT* gene are shown in Table [2](#T2){ref-type="table"}. Our data indicated that all four SNPs investigated were in Hardy-Weinberg equilibrium in the control subjects (*P* \> 0.05). We compared the differences in frequency distributions of alleles between cases and controls by Chi-squared test. No associations were observed between the alleles of the four SNPs and CHB risk in the allele model. We also performed a Bonferroni correction and determined that none of the four SNPs showed statistical significant associations with CHB risk.

###### Basic characteristic of the four SNPs in *TERT*

  SNP-ID       Position   Band      Role     Alleles A/B   HWE     MAF     OR (95% CI)   *P*                 
  ------------ ---------- --------- -------- ------------- ------- ------- ------------- ------------------- -------
  rs10069690   1279790    5p15.33   Intron   T/C           0.347   0.187   0.144         1.37 (0.99--1.90)   0.054
  rs2242652    1280028    5p15.33   Intron   A/G           0.523   0.181   0.160         1.16 (0.84--1.59)   0.357
  rs2853677    1287194    5p15.33   Intron   G/A           0.696   0.366   0.332         1.16 (0.91--1.50)   0.234
  rs2853676    1288547    5p15.33   Intron   T/C           0.817   0.158   0.147         1.09 (0.78--1.52)   0.611

SNP: Single nucleotide polymorphism, A: Minor alleles, B: Major alleles, HWE: Hardy-Weinberg equilibrium, MAF: Minor allele frequency, OR: Odds ratio, 95% CI: 95% Confidence interval.

Genetic models {#s2_3}
--------------

We further assessed the association between each SNP and CHB risk in an unconditional logistic regression analysis, which was performed using four models: genotype, dominant, recessive, and additive model (Table [3](#T3){ref-type="table"}). The SNP rs10069690 was found to be associated with an increased risk of CHB in the dominant model (OR = 1.48, 95% CI: 1.02--2.14, *P* = 0.040; adjusted OR = 1.70, 95% CI: 1.06--2.71, *P* = 0.031) both before and after the adjustment for age, gender, smoking and drinking; and in the additive model (adjusted OR = 1.62, 95% CI: 1.09--2.41, *P* = 0.018) after the adjustment for age, gender, smoking and drinking. No significantly statistical associations were found under the other models.

###### Genetic models analyses of the association between the SNPs and CHB risk

  SNP-ID       Model        Genotype   Case    Control   OR (95% CI)         *P*     OR (95% CI)         *P*^a^
  ------------ ------------ ---------- ------- --------- ------------------- ------- ------------------- --------
  rs10069690   Codominant   TT         8       8         1.37 (0.50--3.72)   0.539   2.73 (0.84--8.88)   0.096
                            TC         75      69        1.49 (1.01--2.19)   0.043   1.60 (0.98--2.60)   0.061
                            CC         160     219       1.00                \-      1.00                \-
               Dominant     TT-TC      83      77        1.48 (1.02--2.14)   0.040   1.70 (1.06--2.71)   0.027
                            CC         160     219                                                       
               Recessive    TT         8       8         1.23 (0.45--3.32)   0.689   2.39 (0.74--7.72)   0.144
                            TC-CC      235     288                                                       
               Additive     \-\--      \-\--   \-\--     1.37 (0.99--1.89)   0.057   1.62 (1.09--2.41)   0.018
  rs2242652    Codominant   AA         8       9         1.16 (0.44--3.08)   0.763   2.05 (0.64--6.55)   0.225
                            AG         72      78        1.21 (0.83--1.76)   0.333   1.22 (0.76--1.98)   0.415
                            GG         163     213       1.00                \-      1.00                \-
               Dominant     AA-AG      80      87        1.20 (0.83--1.73)   0.325   1.29 (0.82--2.05)   0.274
                            GG         163     213                                                       
               Recessive    AA         8       9         1.10 (0.42--2.90)   0.846   1.94 (0.61--6.12)   0.262
                            AG-GG      235     291                                                       
               Additive     \-\--      \-\--   \-\--     1.16 (0.84--1.59)   0.362   1.30 (0.88--1.93)   0.190
  rs2853677    Codominant   GG         28      31        1.28 (0.72--2.28)   0.398   1.81 (0.87--3.77)   0.114
                            GA         122     137       1.26 (0.88--1.81)   0.203   1.43 (0.91--2.25)   0.121
                            AA         93      132       1.00                \-      1.00                \-
               Dominant     GG-GA      150     168       1.27 (0.90--1.79)   0.178   1.49 (0.97--2.31)   0.070
                            AA         93      132                                                       
               Recessive    GG         28      31        1.13 (0.66--1.94)   0.658   1.49 (0.75--2.98)   0.256
                            GA-AA      215     269                                                       
               Additive     \-\--      \-\--   \-\--     1.18 (0.91--1.52)   0.222   1.37 (0.99--1.91)   0.058
  rs2853676    Codominant   TT         3       7         0.55 (0.14--2.17)   0.395   1.42 (0.26--7.73)   0.683
                            TC         71      74        1.24 (0.84--1.81)   0.277   1.23 (0.76--1.98)   0.398
                            CC         170     219       1.00                \-      1.00                \-
               Dominant     TT-TC      74      81        1.18 (0.81--1.71)   0.393   1.24 (0.78--1.97)   0.370
                            CC         170     219                                                       
               Recessive    TT         3       7         0.52 (0.13--2.04)   0.349   1.35 (0.25--7.30)   0.728
                            TC-CC      241     293                                                       
               Additive     \-\--      \-\--   \-\--     1.09 (0.78--1.53)   0.605   1.22 (0.80--1.87)   0.362

SNP: Single nucleotide polymorphism, OR: Odds ratio, 95% CI: 95% Confidence interval aP were adjusted by age, gender, smoking and drinking. *P* \< 0.05 indicates statistical significant.

Haplotype {#s2_4}
---------

The two SNPs rs10069690 and rs2242652 in the *TERT* gene showed significant linkage disequilibrium, as shown in Figure [1](#F1){ref-type="fig"}. In order to assess the associations between SNP haplotypes and CHB risk, a Wald test was performed using an unconditional multivariate regression analysis. The frequency of haplotype "TA" in the case group was significantly higher than that in the health control group. The haplotype "TA" was found to be associated with an increased risk of CHB (adjusted OR = 1.58, 95% CI: 1.05--2.38, *P* = 0.027) adjusted by gender, age, smoking and drinking, as shown in Table [4](#T4){ref-type="table"}.

![Haplotype block map for the four SNPs in *TERT*\
The LD between each pair SNPs is standardized D′, bright red corresponding to s very strong LD; white corresponding to no LD; pink corresponding to intermediate LD.](oncotarget-09-9199-g001){#F1}

###### Haplotype frequencies and associated with CHB risk

  SNPs                    Haplotype   F_A      F_U      OR (95% CI)         *P*
  ----------------------- ----------- -------- -------- ------------------- -------
  rs10069690\|rs2242652   TA          0.1777   0.1385   1.58 (1.05--2.38)   0.027
                          CG          0.8161   0.8395   0.77 (0.52--1.14)   0.194

F_A: Frequency in case, F_U: Frequency in control, OR: Odds ratio, 95% CI: 95% Confidence interval *P*-values were adjusted by gender, age, smoking and drinking. *P* \< 0.05 indicates statistical significance.

DISCUSSION {#s3}
==========

In this case-control study, we investigated the association between SNPs in the *TERT* gene and the risk of CHB in a Chinese Han population. The results showed that rs10069690 was significantly associated with an increased risk of CHB in the dominant model and additive model. In addition, we found that the haplotype "TA" (rs10069690 and rs2242652) was associated with an increased risk of CHB.

TERT gene encodes the catalytic subunit of telomerase reverse transcriptase, which is really important component of telomerase. Several studies have reported that TERT regulates cell proliferation and metastasis, and that it also has a strong effect on alternative splicing and genetic control of telomere length \[[@R21], [@R22]\]. The variants of the TERT has been found to be associated with many types of cancers and aging-related disorders, including glioma \[[@R17]\], lung cancer \[[@R19]\], breast cancer \[[@R12]\], gastric cancer \[[@R23]\], astrocytoma \[[@R18]\] and so on. It has been demonstrated that the genotype TT of *TERT* polymorphism rs2736098 was associated with a decreased risk of CHB in Chinese males \[[@R14]\]. In this study, we found that *TERT* gene polymorphism rs10069690 and haplotype "TA" were associated with CHD risk in a Chinese Han population. We suggested that TERT gene may have association with cancers and disease by influencing the balancing the telomere length. In addition, Telomerase or TERT and telomeres have long been recognized to play pivotal parts in regulating immunological activity \[[@R24]\]. It is thus likely that *TERT* variants modify risk of CHB by influencing host immune function. However, the mechanistic details have not yet been elucidated.

Recently, it was reported that the T allele of rs10069690 was associated with an increased risk of breast cancer \[[@R12]\], lung cancer \[[@R19]\], esophageal cancer \[[@R23]\], gastric cancer \[[@R25]\], coronary heart disease \[[@R26]\]. However, rs10069690 was found to be associated with significantly reduced risk of hepatocellular carcinoma, prostate cancer \[[@R27]\]. We didn't observe any association between the three SNPs (rs2242652, rs2853677and rs2853676) and CHD risk. Previous studies found that the three SNPs were also associated with several cancers risk \[[@R17], [@R23], [@R25], [@R28]\]. To date, there has been little report on the correlation between the polymorphisms of *TERT* and CHB risk. To our knowledge, this is the first report demonstrating an association between the variant rs10069690 and CHB risk, which need to be confirmed in further studies.

It should be noted that this study has limitations. First, the sample size is not large enough, and the CHB patients and controls included only Chinese population lived in Shaanxi Province. Second, the functional assessment of *TERT* genetic variants was not performed. Finally, the potential influences of environmental factors on the results could not be completely eliminated. Therefore, future prospective studies are required to confirm these findings, and the interaction of genetic and environmental factors in the development of CHB, and determine the functional role of these SNPs, with a larger sample.

In conclusion, our study identified that rs10069690 and haplotype "TA" in *TERT* gene are associated with a significantly increased risk of CHB, which may have the potentially to serve as prognostic biomarker for CHB in the Han Chinese population. Further validation of the functionality of the variants and its association with risk of CHB in other ethnic populations is warranted.

MATERIALS AND METHODS {#s4}
=====================

Participants {#s4_1}
------------

A total of 542 unrelated Chinese Han individuals consisting of 242 CHB patients and 300 healthy controls were recruited in the case-control study. All the patients were recruited from the Haikou people's Hospital, and diagnosed as a clinical disease of CHB according to the diagnostic criteria of CHB based on history of hepatitis B virus (HBV) infection, HBsAg/anti-HBs, HBeAg/anti-HBe and anti-HBc serostatus, HBV DNA level, biochemical liver function, ultrasonography and/or computerized tomography (CT)/ magnetic resonance imaging (MRI) \[[@R29]\]. The patients with the family history of liver, renal, endocrine and cardiovascular disorders disease were excluded. The control subjects were randomly selected from physical examination center of the Haikou people's Hospital during the same period, with negativity for HBsAg, HBcAg, anti-HCV and anti-HIV and with no abnormalities based on physical examination. All the subjects were Chinese Han individuals and their ancestors had lived in the region at least the three generations. A uniform questionnaire was used at enrollment including gender, age, smoking and drinking. The characteristics of the participants are shown in Table [1](#T1){ref-type="table"}.

Ethics statement {#s4_2}
----------------

The collected blood samples and the protocol in this study were strictly conformed to the Declaration of Helsinki and were approved by the institutional ethical committee of the Haikou people's Hospital. Written consents were obtained from all participants before participation in the study.

Genotyping {#s4_3}
----------

Five milliliters of peripheral venous blood was obtained from each subject and collected in an EDTA tube, and then the blood samples were stored in a refrigerator at −20°C for DNA extraction. Genomic DNA was extracted from whole blood using the GoldMag-Mini Whole Blood Genomic DNA Purification Kit (GoldMag. Co. Ltd., Xi'an, China) based on the manufacturers' instructions. DNA concentration and purity were evaluated using a spectrophotometer (NanoDrop 2000; Thermo Fisher Scientific, Waltham, MA, USA) at wavelengths of A260 and A280nm.

We selected four SNPs (rs10069690, rs2242652, rs2853677 and rs2853676) from previously reported *TERT* gene polymorphisms \[[@R17], [@R19], [@R23], [@R25], [@R28]\], and matched SNPs with MAF \> 5% in the HapMap of the Chinese Han Beijing population selected for association analysis. The sequences of amplification and extension primers corresponding to each SNP were designed by the Sequenom MassARRAY Assay Design 3.0 Software (Sequenom, San Diego, CA, USA), as showed in Table [5](#T5){ref-type="table"}. Genotyping of the SNPs were performed using the Sequenom MassARRAY platform (Sequenom, San Diego, CA, USA) according to the standard protocol recommended by the manufacturer. We used the Sequenom Typer 4.0 software to perform data management and analyses.

###### The sequences of primers of each SNP

  SNP-ID       2nd-PCRP                         1st-PCRP                         UEP
  ------------ -------------------------------- -------------------------------- -------------------------
  rs10069690   ACGTTGGATGATGTGTGTTGCACACGGGAT   ACGTTGGATGCCTGTGGCTGCGGTGGCTG    GGGATCCTCATGCCA
  rs2242652    ACGTTGGATGAGGCTCTGAGGACCACAAGA   ACGTTGGATGACAGCAGGACACGGATCCAG   gtcgGAGGACCACAAGAAGCAGC
  rs2853677    ACGTTGGATGGCAAGTGGAGAATCAGAGTG   ACGTTGGATGATCCAGTCTGACAGTCGTTG   gggtAATCAGAGTGCACCAG
  rs2853676    ACGTTGGATGCAAAACTAAGACCCAAGAGG   ACGTTGGATGTGTCTCCTGCTCTGAGACC    agatGGAAGTCTGACGAAGGC

SNP: Single nucleotide polymorphism; PCRP: Polymerase chain reaction primer; UEP: unique base extension primer Sequences are written in the 5 ′ →3 ′ (left to right) orientation.

Statistical analysis {#s4_4}
--------------------

All statistical analyses were performed using the SPSS 19.0 statistical software (SPSS, Chicago, IL) and Microsoft Excel. We used the Pearson's χ^2^ test and Welch's *t* test to evaluate the differences in the demographic characteristics between the cases and controls. The Hardy-Weinberg equilibrium (HWE) of each SNP was assessed in order to compare the expected frequencies of the genotypes in the controls using χ^2^ test. The allele frequencies of the two groups were compared with chi-square test, and to evaluate associations between the SNPs and risk of CHB in the four models (genotype, dominant, recessive, and additive). Linkage disequilibrium analysis and SNP haplotypes were analyzed using the Haploview software package (version 4.2). The relative risk was estimated by odd ratios (ORs) and 95% confidence intervals (CIs) using unconditional logistic regression analysis. The *P*-value \< 0.05 was considered statistically significant and all statistical tests were two-sided.
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